

CSPC PHARMACEUTICAL GROUP LTD.

ISIN: HK1093012172 WKN: - Asset Class: Stock

Company

2024/04/10 07:33:19

Price

6.23 HKD

Difference  0.16%(0.01)



Contact Details

CSPC PHARMACEUTICAL
GROUP LTD.

--

No. 226 Huanghe Street

050035 Shijiazhuang

Tel: +86-311-8703-7015

Fax: +86-311-8703-9608

Web:

<http://www.cspc.com.hk>

E-mail: info@cpg.hk

Company Profile

CSPC Pharmaceutical Group Ltd. is an investment holding company, which is engaged in the manufacturing and selling of pharmaceutical products. It operates through the following business segments: Finished Drugs, Antibiotics, Vitamin C, Caffeine and Others. The company was founded on August 21, 1997 and is headquartered in Shijiazhuang, China.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	29,446,326,000		26,897,656,000		24,876,945,000	
Common stock capital		12,000,310,000		12,237,203,000		13,332,876,000
Fixed assets	21,510,588,000		19,998,929,000		17,621,230,000	
Equity capital of a company		38,555,017,000		35,525,591,000		32,818,052,000
Cash and cash equivalents	13,228,824,000		11,561,981,000		11,356,360,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		11,211,067,000		10,057,502,000		8,839,370,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		1,190,830,000		1,009,322,000		534,694,000
Different income		-		-		-
Other liabilities		440,054,000		0		0
Total assets	50,956,915,000	50,956,915,000	46,896,586,000	46,896,586,000	42,498,175,000	42,498,175,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	23,500	24,837	24,746
Equity ratio	79.58%	79.21%	79.64%
Debt-equity ratio	25.65%	26.25%	25.56%

Others

	2023	2022	2021
Tax Expense Rate	17.69%	17.77%	16.98%

CSPC PHARMACEUTICAL GROUP LTD.

ISIN: HK1093012172 WKN: - Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	34,752,307,000	35,975,851,000	33,585,456,000
Net income	6,490,012,000	7,083,544,000	6,755,430,000
EBIT	939,259,166	1,011,825,251	944,796,416
Operating income before taxes	8,225,127,000	8,835,148,000	8,225,146,000
Cash Flow	-	9,225,191,000	5,862,517,000
Net interest income	258,552,000	253,085,000	211,606,000
Research and development expenses	5,337,554,000	4,635,832,000	4,136,995,000
Income taxes	1,454,927,000	1,570,130,000	1,396,805,000
Result from investments in subsidiaries, associates and other	-59,886,000	-17,902,000	27,048,000
Revenues per employee	174,353	170,776	160,015

Board of Directors

Dong Chen Cai	Chairman of Supervisory Board
Hao Jiang	Member of Supervisory Board
Hong Guang Wang	Member of Supervisory Board
Qingxi Wang	Member of Supervisory Board
Bo Wang	Member of Supervisory Board
Cheuk Kin Law	Member of Supervisory Board
Chuan Chen	Member of Supervisory Board
Chun Kwok Au	Member of Supervisory Board
Chun Lei Li	Member of Supervisory Board
Huai Yu Wang	Member of Supervisory Board
Kin Man Chak	Member of Supervisory Board
Quan Li	Member of Supervisory Board
Wei Dong Pan	Member of Supervisory Board
Zhen Guo Wang	Member of Supervisory Board

Members of Management Board

CAI Dongchen	Chairman of Managing Board
CHAK Kin Man	Member of Executive Committee
JIANG Hao	Member of Executive Committee
LI Chunlei	Member of Executive Committee
PAN Weidong	Member of Executive Committee
WANG Huaiyu	Member of Executive Committee
WANG Qingxi	Member of Executive Committee
WANG Zhenguo	Member of Executive Committee
ZHANG Cuilong	Member of Executive Committee